Literature DB >> 11695848

Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.

N Hanioka1, S Ozawa, H Jinno, M Ando, Y Saito, J Sawada.   

Abstract

1. The human liver UDP-glucuronosyltransferase (UGT) isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), have been studied using microsomes from human liver and insect cells expressing human UGTs (1A1, 1A3, 1A4, 1A6, 1A9, 2B7, 2B15). 2. The glucuronidation of SN-38 was catalysed by UGT1A1, UGT1A3, UGT1A6 and UGT1A9 as well as by liver microsomes. Among these UGT isoforms, UGT1A1 showed the highest activity of SN-38 glucuronidation at both low (1 microM) and high (200 microM) substrate concentrations. The ranking in order of activity at low and high substrate concentrations was UGT1A1 > UGT1A9 > UGT1A6 > UGT1A3 and UGT1A1 > UGT1A3 > UGT1A6 > or = UGT1A9, respectively. 3. The enzyme kinetics of SN-38 glucuronidation were examined by means of Lineweaver-Burk analysis. The activity of the glucuronidation in liver microsomes exhibits a monophasic kinetic pattern, with an apparent Km and Vmax of 35.9 microM and 134 pmol min(-1) mg(-1) protein, respectively. The UGT isoforms involved in SN-38 glucuronidation could be classified into two types: low-Km types such as UGT1A1 and UGT1A9, and high-Km types such as UGT1A3 and UGT1A6, in terms of affinity toward substrate. UGT1A1 had the highest Vmax followed by UGT1A3. Vmax of UGT1A6 and UGT1A9 were approximately 1/9 to 1/12 of that of UGT1A1. 4. The activity of SN-38 glucuronidation by liver microsomes and UGT1A1 was effectively inhibited by bilirubin. Planar and bulky phenols substantially inhibited the SN-38 glucuronidation activity of liver microsomes and UMT1A9, and/or UGT1A6. Although cholic acid derivatives strongly inhibited the activity of SN-38 glucuronidation by UGT1A3, the inhibition profile did not parallel that in liver microsomes. 5. These results demonstrate that at least four UGT1A isoforms are responsible for SN-38 glucuronidation in human livers, and suggest that the role and contribution of each differ substantially.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11695848     DOI: 10.1080/00498250110057341

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  24 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.

Authors:  Jacqueline Ramírez; Snezana Mirkov; Larry K House; Mark J Ratain
Journal:  Drug Metab Dispos       Date:  2015-04-13       Impact factor: 3.922

3.  Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

Authors:  Jin Zhou; Timothy S Tracy; Rory P Remmel
Journal:  Drug Metab Dispos       Date:  2010-10-28       Impact factor: 3.922

Review 4.  Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis.

Authors:  Baojian Wu; Sumit Basu; Shengnan Meng; Xiaoqiang Wang; Ming Hu
Journal:  Curr Drug Metab       Date:  2011-11       Impact factor: 3.731

5.  Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1.

Authors:  Baojian Wu; Shuxing Zhang; Ming Hu
Journal:  Mol Pharm       Date:  2011-10-21       Impact factor: 4.939

6.  Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.

Authors:  Qingyu Zhou; Alex Sparreboom; Eng-Huat Tan; Yin-Bun Cheung; Ann Lee; Donald Poon; Edmund J D Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

7.  The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.

Authors:  Yong Liu; Jacqueline Ramírez; Larry House; Mark J Ratain
Journal:  Eur J Cancer       Date:  2010-05-23       Impact factor: 9.162

Review 8.  FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.

Authors:  Beatrice Mohelnikova-Duchonova; Bohuslav Melichar; Pavel Soucek
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

9.  Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

Authors:  Eric Lévesque; Anne-Sophie Bélanger; Mario Harvey; Félix Couture; Derek Jonker; Federico Innocenti; Erica Cecchin; Giuseppe Toffoli; Chantal Guillemette
Journal:  J Pharmacol Exp Ther       Date:  2013-02-05       Impact factor: 4.030

10.  Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells.

Authors:  Anne-Sophie Bélanger; Jelena Tojcic; Mario Harvey; Chantal Guillemette
Journal:  BMC Mol Biol       Date:  2010-01-22       Impact factor: 2.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.